New Claim 30. A pharmaceutical composition comprising a free base or a pharmaceutically acceptable salt of said liver CYP1A according to claim 28.

B'ent

New Claim 31. The pharmaceutical composition according to claim 30, wherein said pharmaceutical composition inhibits liver cytochrome P450 1A enzymatic activity.

New Claim 32. The pharmaceutical composition according to claim 31, wherein said liver cytochrome P450 1A enzymatic activity is a first-pass metabolism of a drug.

REMARKS

On March 18, 2003, Applicants filed a response to the Office Action dated December 18, 2002. After the submission of the response, Applicants realized that they should be entitled to claims that are directed to certain compounds that have inhibitory effect on liver cytochrome P450 1A. Particularly, some of the compounds which have inhibitory effect on dermal cytochrome P450 1A also demonstrated inhibitory effect on liver cytochrome P450 1A, another group of cytochrome P450 1A enzymes which are different from that of the dermal cytochrome P450 1A enzyme. Applicants therefore respectfully submit this supplemental amendment to further claim the liver cytochrome P450 1A inhibitors. The support for these new claims can be found in Table 2 and its related text. No new matter has been introduced.

In view of the foregoing, all objection and rejections have been overcome and all claims are in condition for allowance, early notice of which is requested. Should the application not be allowed, the examiner is requested to contact Applicants' attorney to resolve the issue.

No fee is believed to be due. Should any fee be required, please charge the same to deposit account number 22-0261 and notify Applicants' attorney.

Respectfully submitted,

Fei-Fei Chao, Ph.D.

Fir-Fin Chao

Reg. No. 43,538

Date: April 1, 2003

Fei-Fei Chao, Ph.D. Venable, Baetjer, Howard & Civiletti, LLP 1201 New York Avenue, N.W., Suite 1000 Washington, D.C. 20005

Tel.: (202) 216-8011

doc# 443519